ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

4CMenB vaccine

Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.

In GlaxoSmithKline’s pipeline, Recombinant protein and outer membrance vesicle vaccine. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.

Drug page4CMenB vaccine: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 2, 200831 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only130 open or runningphase 3since Apr 2, 2008Feb 27, 2006none ahead
Pfizerits history only90 open or runningphase 4since May 14, 2021Oct 11, 2006none ahead
GlaxoSmithKlineits history only71 open or runningphase 4since Feb 6, 2018Feb 14, 2014none ahead
Sanofi20 open or runningphase 3since Sep 4, 2019Sep 4, 2019none ahead
  • Named in GlaxoSmithKline’s own pipeline as Men B vaccine GSK3536829, phase 3, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 4, 2019First study: phase 3 study in Meningococcal Immunisation (Healthy Volunteers)First studyNCT04084769 · 570 enrolled · United States, Puerto Rico
  2. Oct 26, 2023Phase 2 study in Meningococcal ImmunisationNCT06128733 · 1,215 enrolled · United States, Puerto Rico

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule

Studies

All 2 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06128733Meningococcal Immunisation · United States, Puerto Rico2CompletedAug 27, 20251,215
NCT04084769Meningococcal Immunisation (Healthy Volunteers) · United States, Puerto Rico3CompletedSep 14, 2020570

How it is read

Names in the registry

  • “rLP2086”, 11 entries
  • “rMenB+OMV NZ”, 9 entries
  • “Meningococcal B vaccine”, 6 entries
  • “rMenB+OMV NZ vaccine”, 3 entries
  • “Meningococcal group B vaccine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.